TSXV:ACST

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. More Details


Snowflake Analysis

Adequate balance sheet with moderate growth potential.


Similar Companies

Share Price & News

How has Acasti Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ACST is more volatile than 90% of Canadian stocks over the past 3 months, typically moving +/- 31% a week.

Volatility Over Time: ACST's weekly volatility has increased from 23% to 31% over the past year.


Market Performance


7 Day Return

-11.6%

ACST

9.0%

CA Pharmaceuticals

0.2%

CA Market


1 Year Return

-24.0%

ACST

47.4%

CA Pharmaceuticals

1.5%

CA Market

Return vs Industry: ACST underperformed the Canadian Pharmaceuticals industry which returned 46.7% over the past year.

Return vs Market: ACST underperformed the Canadian Market which returned 1.6% over the past year.


Shareholder returns

ACSTIndustryMarket
7 Day-11.6%9.0%0.2%
30 Day126.9%30.1%3.6%
90 Day192.3%76.7%13.3%
1 Year-24.0%-24.0%47.4%47.4%5.2%1.5%
3 Year-46.1%-46.1%-52.9%-53.6%13.1%2.3%
5 Year-67.7%-67.7%417.8%414.2%69.3%43.3%

Long-Term Price Volatility Vs. Market

How volatile is Acasti Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Acasti Pharma undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: ACST (CA$0.77) is trading below our estimate of fair value (CA$11.01)

Significantly Below Fair Value: ACST is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: ACST is unprofitable, so we can't compare its PE Ratio to the CA Pharmaceuticals industry average.

PE vs Market: ACST is unprofitable, so we can't compare its PE Ratio to the Canadian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ACST's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ACST is overvalued based on its PB Ratio (6.6x) compared to the CA Pharmaceuticals industry average (2.7x).


Next Steps

Future Growth

How is Acasti Pharma forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

80.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ACST is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.5%).

Earnings vs Market: ACST is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ACST's is expected to become profitable in the next 3 years.

Revenue vs Market: Insufficient data to determine if ACST's revenue is forecast to grow faster than the Canadian market.

High Growth Revenue: Insufficient data to determine if ACST's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ACST's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Acasti Pharma performed over the past 5 years?

-32.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ACST is currently unprofitable.

Growing Profit Margin: ACST is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ACST is unprofitable, and losses have increased over the past 5 years at a rate of 32.3% per year.

Accelerating Growth: Unable to compare ACST's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ACST is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-61.1%).


Return on Equity

High ROE: ACST has a negative Return on Equity (-71.24%), as it is currently unprofitable.


Next Steps

  • Explore strong past performing companies in the Pharmaceuticals & Biotech industry.

Financial Health

How is Acasti Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: ACST's short term assets ($13.7M) exceed its short term liabilities ($3.8M).

Long Term Liabilities: ACST's short term assets ($13.7M) exceed its long term liabilities ($1.2M).


Debt to Equity History and Analysis

Debt Level: ACST is debt free.

Reducing Debt: ACST had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ACST has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: ACST has less than a year of cash runway if free cash flow continues to reduce at historical rates of 28.2% each year


Next Steps

Dividend

What is Acasti Pharma current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ACST's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ACST's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ACST's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ACST's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ACST's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.2yrs

Average board tenure


CEO

Jan D' Alvise (65 yo)

4.58yrs

Tenure

US$2,186,347

Compensation

Ms. Janelle D’ Alvise, also known as Jan, has been the Chief Executive Officer and President of Acasti Pharma Inc. since June 01, 2016 and also serves as its Corporate Secretary. Ms. D’Alvise served as Chi...


CEO Compensation Analysis

Compensation vs Market: Jan's total compensation ($USD2.19M) is above average for companies of similar size in the Canadian market ($USD153.12K).

Compensation vs Earnings: Jan's compensation has increased whilst the company is unprofitable.


Board Members

NamePositionTenureCompensationOwnership
Janelle D' Alvise
President4.58yrsUS$2.19m0.054%
$ 39.9k
Donald Olds
Independent Director2.75yrsUS$137.07k0.039%
$ 28.9k
Jean-Marie Canan
Independent Director4.5yrsUS$147.54k0.10%
$ 76.0k
Barry Franklin
Member of Scientific Advisory Board3.83yrsno datano data
Roderick Carter
Independent Chairman of the Board4.83yrsUS$192.03k0%
$ 0
Kevin Maki
Member of Scientific Advisory Boardno datano datano data
Robert Hegele
Member of Scientific Advisory Board3.83yrsno datano data
Harold Bays
Member of Scientific Advisory Boardno datano datano data
Dariush Mozaffarian
Member of Scientific Advisory Boardno datano datano data

4.2yrs

Average Tenure

62yo

Average Age

Experienced Board: ACST's board of directors are considered experienced (4.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 13.6%.


Top Shareholders

Company Information

Acasti Pharma Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Acasti Pharma Inc.
  • Ticker: ACST
  • Exchange: TSXV
  • Founded: 2002
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$73.638m
  • Shares outstanding: 96.89m
  • Website: https://www.acastipharma.com

Number of Employees


Location

  • Acasti Pharma Inc.
  • 545, Promenade du Centropolis
  • Suite 100
  • Laval
  • Quebec
  • H7T 0A3
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ACSTTSXV (TSX Venture Exchange)YesClass A SharesCACADMar 2011
ACSTNasdaqCM (Nasdaq Capital Market)YesClass A SharesUSUSDMar 2011
A1PADB (Deutsche Boerse AG)YesClass A SharesDEEURMar 2011

Biography

Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate i...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/19 00:39
End of Day Share Price2021/01/18 00:00
Earnings2020/09/30
Annual Earnings2020/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.